ANP's mission is to develop cutting-edge technology platforms at the nano/bio interface and apply them in market sectors such as diagnostics/biodetection, protein/drug discovery, therapeutics, chem/bio defense, and homeland security.
Anteo Diagnostics specialises in the development and commercialisation of proprietary surface coatings for applications in the diagnostics and biotech industries. With Mix&Go we have developed ?molecular glues? which are used by our partners and customers to immobilize delicate biological molecules such as antibodies to synthetic surfaces.
The company develops biomedical nanoparticle technology and products for research and treatment of human disease. They are developing NanoElectroPlex™, a proprietary tissue selective nanoparticle platform technology based on biodegradable macromolecular carriers.
ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and next generation antibodies and subunit vaccines through its proprietary Twin Cassette yeast system.
Aposense is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death).
Arrayit Corporation empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
Attana AB develops and sells biosensors for analysis of biomolecular interactions. Attana's biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
AuraSense's uniquely engineered nanoparticles possess unparalleled biocompatibility and versatility as therapeutics and as novel assays within live cells. They hold great promise for combating the most threatening diseases, including heart disease, cancer, and bacterial infection.
The company was founded for the purpose of research and development of new therapies for the treatment of specific and hitherto incurable forms of leukaemia. Its business is the production, research and development of targeted pharmaceuticals based on nanoparticle structures.
A specialty pharmaceutical company with a novel drug delivery system. Its proprietary Protein Stabilized Liposomes nanotechnology platform addresses the significant problems associated with delivery of water insoluble drugs.
Beckman Coulter, Inc. is a leading manufacturer of biomedical testing instrument systems, tests and supplies that simplify and automate laboratory processes. Spanning the biomedical testing continuum – from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing – Beckman Coulter's 200,000 installed systems provide essential biomedical information to enhance health care around the world.